Group 2 innate lymphoid cells boost CD8
CD8 T cell
ILC2
anti-tumor response
antigen presentation
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
16
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Group 2 innate lymphoid cells (ILC2s) are essential for orchestrating type 2 immune responses during allergic airway inflammation and infection. ILC2s have been reported to play a regulatory role in tumors; however, this conclusion is controversial. In this study, we showed that IL-33-activated ILC2s could boost CD8
Identifiants
pubmed: 37577145
doi: 10.1080/2162402X.2023.2243112
pii: 2243112
pmc: PMC10413917
doi:
Substances chimiques
Interleukin-33
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2243112Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the authors.
Références
Immunity. 2015 Jul 21;43(1):161-74
pubmed: 26092469
Mucosal Immunol. 2016 Nov;9(6):1407-1417
pubmed: 26883724
Nat Immunol. 2021 Feb;22(2):166-178
pubmed: 33432227
Nature. 2021 Dec;600(7890):707-712
pubmed: 34853467
Nature. 2010 Jan 28;463(7280):540-4
pubmed: 20023630
Science. 2015 May 22;348(6237):aaa6566
pubmed: 25999512
Nat Commun. 2020 Apr 14;11(1):1794
pubmed: 32286285
J Allergy Clin Immunol. 2016 Sep;138(3):801-811.e9
pubmed: 27177780
Biochem Biophys Res Commun. 2022 Dec 31;637:9-16
pubmed: 36375254
Cell Physiol Biochem. 2014;33(3):633-45
pubmed: 24642893
Nat Rev Immunol. 2019 Oct;19(10):599-613
pubmed: 31350531
J Neurooncol. 2017 Jun;133(2):223-235
pubmed: 28434112
Immunogenetics. 2016 Aug;68(8):677-91
pubmed: 27368413
Cell Mol Immunol. 2019 Mar;16(3):225-235
pubmed: 30792500
Cancer Lett. 2021 Apr 1;502:34-43
pubmed: 33429004
Immunity. 2014 Aug 21;41(2):283-95
pubmed: 25088770
Annu Rev Immunol. 1994;12:337-65
pubmed: 8011285
J Clin Invest. 2017 Aug 1;127(8):2916-2929
pubmed: 28650339
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
Nat Immunol. 2021 Jul;22(7):851-864
pubmed: 34099918
J Transl Med. 2010 Sep 28;8:90
pubmed: 20920165
Nature. 2020 Mar;579(7797):130-135
pubmed: 32076273
Cancer Cell. 2016 Aug 8;30(2):324-336
pubmed: 27424807
Front Immunol. 2021 Aug 31;12:733136
pubmed: 34531874
Nat Commun. 2016 Sep 01;7:12651
pubmed: 27582256
Clin Rev Allergy Immunol. 2016 Jun;50(3):312-32
pubmed: 26215166
Haematologica. 2015 Jul;100(7):e257-60
pubmed: 25710455
Sci Immunol. 2017 Dec 22;2(18):
pubmed: 29273672
Front Immunol. 2019 Dec 03;10:2801
pubmed: 31849977
Immunity. 2012 Oct 19;37(4):649-59
pubmed: 23063330
Nat Commun. 2017 Sep 19;8(1):593
pubmed: 28928446
J Immunol. 2000 Oct 1;165(7):3797-803
pubmed: 11034385
J Clin Invest. 2020 Feb 3;130(2):774-788
pubmed: 31661470
Nat Rev Immunol. 2022 Nov;22(11):701-712
pubmed: 35354980